Dr. Natalie Nunez Gomez, Head of Global Medical Affairs, Psoriasis at UCB, discusses new, interim long-term results from the bimekizumab BE BRIGHT open-label extension study presented at the European Academy of Dermatology and Venereology (EADV) Congress, as well as additional findings from the Phase 3/3b clinical program for bimekizumab in psoriasis.
Natalie Nunez Gomez is a Medical Doctor and is currently Head of Global Medical Affairs for psoriasis at UCB, where she leads medical strategy and scientific activities. With over 17 years’ experience in the pharmaceutical industry in roles across global, US and Germany, Natalie is widely experienced in the launch of pharmaceutical products with a specific focus in the areas of immunology and dermatology. Prior to joining the pharmaceutical industry, Natalie also worked as a physician in the dermatology department of the Ludwig-Maximilian-University of Munich (LMU) in Germany. Natalie holds a Medical Degree from the LMU in Munich, Germany.